Predictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a randomised controlled trial.
Conlin K. et al, (2024), Vaccine, 45
Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study.
Costa Clemens SA. et al, (2024), Lancet Microbe, 5
Multi-omics analysis reveals COVID-19 vaccine induced attenuation of inflammatory responses during breakthrough disease.
Drury RE. et al, (2024), Nat Commun, 15
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials.
Voysey M. et al, (2023), Clin Exp Immunol, 211, 280 - 287
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
Feng S. et al, (2021), Nature Medicine
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Ramasamy MN. et al, (2021), Lancet, 396, 1979 - 1993
AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific TH1 response with a diverse TCR repertoire.
Swanson PA. et al, (2021), Sci Transl Med, 13
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
Flaxman A. et al, (2021), Lancet, 398, 981 - 990
Antibody evasion by the P.1 strain of SARS-CoV-2.
Dejnirattisai W. et al, (2021), Cell, 184, 2939 - 2954.e9
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera.
Zhou D. et al, (2021), Cell, 184, 2348 - 2361.e6
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera.
Supasa P. et al, (2021), Cell, 184, 2201 - 2211.e7
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
Emary KRW. et al, (2021), Lancet, 397, 1351 - 1362
A haemagglutination test for rapid detection of antibodies to SARS-CoV-2.
Townsend A. et al, (2021), Nat Commun, 12
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Voysey M. et al, (2021), Lancet, 397, 881 - 891